ELEVAI Labs Inc, a medical aesthetic biotechnology company specializing in physician-dispensed skincare, announced the addition of Crystal Muilenburg as an independent member of the companyโ€™s Board of Directors.

According to the company, Mullenburg brings more than two decades of experience in marketing, corporate communications, and public relations for global Fortune 500 companies and public-company start-ups. She reportedly will play a key role in supporting the ELEVAI management team as it commercializes ELEVAIโ€™s flagship exosome product line while driving the market adoption for physician-dispensed topical exosomes.

โ€œIโ€™m thrilled to join ELEVAI as they lead the aesthetics industry and as they establish a new segment of physician-dispensed skincare products harnessing topical exosomes,โ€ said Muilenburg. โ€œWith a science-first approach, an industry-leading management team, and the marketโ€™s interest in the novel approach to skin leveraging the power of exosomes, ELEVAIโ€™s future is bright.โ€

Most recently, Mullenburg served as chief marketing officer for Evolus where she led the re-launch of Jeuveau, a disruptor brand to BOTOX Cosmetic. Under her leadership, Jeuveau became one of the fastest-growing neurotoxins in the United States and one of the top product launches in aesthetics history.

Prior to Evolus, Mullenburg was head of global strategic marketing for Sienna Biopharmaceuticals, a publicly traded, clinical-stage medical dermatology company. She also spent more than a decade at Allergan in various leadership roles in U.S. and International marketing and communications where she reportedly gained significant FDA approval and commercial launch experience with the companyโ€™s flagship BOTOX franchise and leading aesthetics brands.

โ€œWe are excited to welcome Crystal to ELEVAIโ€™s Board,โ€ said Jordan R. Plews, PhD, ELEVAIโ€™s founder โ€œWe believe her track record, accomplishments, and science-first approach will help propel ELEVAI in becoming the preferred topical exosome company as this segment continues to grow in interest and demand.โ€